Server: Netscape-Commerce/1.1 Date: Thursday, 18-Dec-97 18:21:18 GMT Last-modified: Thursday, 30-Oct-97 15:29:01 GMT Content-length: 10206 Content-type: text/html
![]() |
10/29/97 | OraVax, Inc. to Conduct Phase III Clinical Trial for Respiratory Syncytial Virus in Infants in Winter 1998-1999 |
![]() |
10/23/97 | OraVax, Inc. Reports 1997 Third Quarter
Results
-- Company Enters Yellow Fever U.S. Marketing and Distribution Agreement with Evans Medical Limited and Acquires ChimeriVaxTM Technology Platform -- |
![]() |
10/20/97 | NIH Awards OraVax Phase II SBIR Grant for the Clinical Development of New Treatments for Clostridium difficile Associated Disease |
![]() |
09/29/97 | OraVax and Evans Medical Sign U.S.
Marketing and Distribution Agreement for Yellow Fever Vaccine
-- OraVax To Assist With U.S. Registration |
![]() |
09/16/97 | OraVax Acquires Chimeric Vaccine
Technology from St. Louis University
-- Patent Filing Covers a New Class of Single-Dose Viral Vaccines -- |
![]() |
07/30/97 | OraVax, Inc. Announces 1997 Second Quarter and Six Month Results |
![]() |
04/25/97 | OraVax, Inc. Announces 1997 First Quarter Results |
![]() |
04/04/97 | OraVax, Inc. Adopts Shareholder Rights Plan |
![]() |
04/03/97 | OraVax Announces Reorganization; Reduces
Operating Costs
--Robert J. Gerety, M.D., Ph.D., Named Vice President of Development and Regulatory Affairs-- |
![]() |
03/19/97 | OraVax Reports Results from Phase III Trial of HNK20 Nosedrop for Respiratory Syncytial Virus in Infants |
![]() |
03/10/97 | OraVax names C. Boyd Clarke, President of
U.S. Bioscience, to Board of Directors.
-- Engineered Joint Venture Between Merck and Pasteur-Mérieux -- |
![]() |
03/03/97 | OraVax Reports Fourth-Quarter and
Year-End results
-- Clinical Progress in Two Lead Programs Highlight Year -- |
![]() |
11/25/96 | Complete H. Pylori Genome Sequence Licensed to OraVax And Pasteur Mérieux Connaught in Exclusive agreement with MedImmune and Human Genome Sciences for Development of Novel Vaccines |
![]() |
11/14/96 | OraVax Grants bioMérieux Vitek
License to CagA Antigen For H. pylori In Vitro Diagnostic
Tests
-- Out-Licensing Strategy Complements Core Vaccine |
![]() |
10/23/96 | Oravax Reports 1996 Third Quarter Results
-- Successful Phase II Trial of Oral Therapeutic Vaccine Against H. pylori and Progress in Phase III Trial of HNK-20 Highlight |
![]() |
10/17/96 | OraVax and Pasteur Mérieux
Connaught Demonstrate Reduction of H. pylori Infection in
Subjects Receiving Oral Vaccine
-- Clinical Study Demonstrates Immune Responses and Reduced H. pylori Infection -- |
![]() |
09/26/96 | OraVax Updates Investors at Cowen &
Company's 11th Annual Biotechnology Conference
-- Phase 2 safety and immunogenicity study of H. pylori oral vaccine complete; data to be presented at October H. pylori conference -- |
![]() |
08/07/96 | OraVax, Inc. Reports 1996 Second Quarter
Results
-- Commencement of Phase 3 trials and regional marketing partnership for HNK20 highlight quarter -- |
![]() |
08/05/96 | U.S. Patent Issues For OraVax, Inc.'s Oral Treatment of H. pylori Infection |
![]() |
07/08/96 | OraVax, Inc. Announces Exercise of Over-Allotment Option |
![]() |
06/26/96 | OraVax, Inc. Announces Public Offering of 2.0 Million Shares of Common Stock |